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Abstract
Background: Over the past few decades, drug and overall healthcare expenditure have risen
rapidly in most countries. The present study investigates the attitudes and the factors which
influence physician prescribing decisions and practice in Greece and Cyprus.
Methods: A postal questionnaire was developed by researchers at the Department of Health
Economics at the National School of Public Health in Greece, specifically for the purposes of the
study. This was then administered to a sample of 1,463 physicians in Greece and 240 physicians in
Cyprus, stratified by sex, specialty and geographic region.
Results: The response rate was 82.3% in Greece and 80.4% in Cyprus. There were similarities but
also many differences between the countries. Clinical effectiveness is the most important factor
considered in drug prescription choice in both countries. Greek physicians were significantly more
likely to take additional criteria under consideration, such as the drug form and recommended daily
dose and the individual patient preferences. The list of main sources of information for physicians
includes: peer-reviewed medical journals, medical textbooks, proceedings of conferences and
pharmaceutical sales representatives. Only half of prescribers considered the cost carried by their
patients. The majority of doctors in both countries agreed that the effectiveness, safety and efficacy
of generic drugs may not be excellent but it is acceptable. However, only Cypriot physicians actually
prescribe them. Physicians believe that new drugs are not always better and their higher prices are
not necessarily justified. Finally, doctors get information regarding adverse drug reactions primarily
from the National Organisation for Medicines. However, it is notable that the majority of them do
not inform the authorities on such reactions.
Conclusion:  The present study highlights the attitudes and the factors influencing physician
behaviour in the two countries and may be used for developing policies to improve their choices
and hence to increase clinical and economic effectiveness and efficiency.
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Background
Over the past few decades, pharmaceutical expenditure
has risen rapidly in most western countries and this has
been a reason for concern to policymakers, who have
reacted with healthcare reforms and measures to guaran-
tee the sustainability of their health care systems [1]. In
the countries of the Organisation for Economic Coopera-
tion and Development (OECD), pharmaceutical expend-
iture accounts, on average, for about 1.5% of the Gross
Domestic Product (GDP). It is notable however that it
grows, in real terms, by 4.6% annually, which is higher
than the growth rate of total healthcare expenditure or the
growth rate of GDP [2]. Alongside the concern regarding
the growth of pharmaceutical expenditure, there is also a
increasing concern regarding irrational, inappropriate, or
sometimes even harmful prescribing [3,4]. The latter mat-
ter has two manifestations. On the one hand, there is
plenty of evidence from observational or experimental
studies that, for several reasons many of which have been
identified, eligible patients are not always prescribed the
pharmaceutical therapies indicated for their condition.
On the other hand, there is also evidence about over and
misuse of pharmaceutical products. The consequence of
the above can be the loss of health and quality of life ben-
efit for patients and society and the increase of health care
expenditure [5]. Thus, for health and economic reasons, it
is important to follow the recommended optimal and
established drug prescription guidelines.
In this context, a lot of research is trying to analyse and to
understand the factors which influence physician pre-
scribing decisions and practice. The related literature sug-
gests several factors that may have a role in influencing the
prescribing behaviour of physicians [6-9]. Some factors
are fixed and they do not offer any opportunity for modi-
fication and improvements in prescribing behaviour.
Such factors for instance include, the age and sex of the
physician or the patient, the socio-economic characteris-
tics of the practicing area or the reimbursement status of
therapy [10,11]. On the other hand, there are factors
which can be influenced and in turn cause a modification
to the prescribing behaviour of physicians. Such factors
may be the under and post graduate education and the
experience of the physician, various social factors, the
number of practitioners in a practice and others [12-15].
It is notable that no other study has attempted so far to
analyse the prescribing behaviour and its determinants
amongst Greek or Cypriot primary care physicians. There-
fore, we carried out a survey in order to investigate the pre-
scribing attitudes of physicians in these two countries and
in the present paper we present the main survey results.
The paper outlines in a comparative and detailed way the
main factors influencing the decision making and the
drug prescription choices of physicians in the two coun-
tries. More specifically, it reveals the criteria which justify
prescription choice, the sources of physician information,
the attitudes towards generic or new innovative drugs, the
importance of the drug cost in the decision, etcetera. This
information can help policy makers to identify the meas-
ures needed to improve the effectiveness of health policy
and consequently it can contribute towards a greater eco-
nomic and clinical efficiency and effectiveness in the two
countries under consideration.
Organisation of Health System in Greece and in Cyprus
The Greek health care system has characteristics from both
the Beveridge (Social Security) and the Bismarck (Social
Insurance) health organisation model. Specifically, a
National Health Service (NHS) was established in 1983,
with the aim to provide on behalf of the state health care
services to all citizens. In this context, services are pro-
vided by public secondary and tertiary care hospitals and
by primary care units, which are located in semi-urban
and rural areas. There are also a few thousand primary
care physicians doing after graduation compulsory train-
ing in rural areas. The NHS is funded by taxation and by
payments coming from many existing Public Insurance
Sickness Funds. However, it is notable that the Sickness
Funds also operate on their own several primary care
health units and hospitals. Finally, alongside the above
there is a significant in size private health care sector, com-
prising freelancing or contracted physicians, diagnostic
centres and hospitals. There are no general practitioners,
to act as gatekeepers to the healthcare system in Greece.
Thus, regarding their health problem, patients can consult
with any physician within the primary or secondary
health care system. In Cyprus healthcare delivery depends
on both public and private health units as well. The public
sector is mostly responsible for the provision of secondary
and tertiary care and the private sector is responsible for
the provision of primary health care services. It is notable
that in this country as well there is no gate-keeping system
at present, meaning that patients are free to select and
consult with any physician of their choice [16].
Methods
A questionnaire was developed by the Department of
Health Economics at the National School of Public Health
in Greece, specifically for the purposes of the survey. The
questionnaire is divided into seven different sections: the
first is designed to investigate the determinants of physi-
cian prescribing behaviour and their main sources of
information; the second reflects their opinion about the
cost of pharmaceuticals to the patient; the third section
focuses on attitudes towards the prescription of generics;
the fourth section reflects attitudes towards new pharma-
ceutical products; the fifth section is about adverse drug
reactions and safety; the sixth section focuses on pharma-
ceutical company sales representatives; and the last sec-BMC Health Services Research 2009, 9:150 http://www.biomedcentral.com/1472-6963/9/150
Page 3 of 9
(page number not for citation purposes)
tion includes questions about the demographic
characteristics of the person answering. In total, the ques-
tionnaire included 47 semi-closed questions. It was
piloted to a group of 217 physicians in Greece in the
period between the November of 2006 and January of
2007. The physicians who participated in the pilot study
made significant comments towards the improvement of
the instrument and all of their recommendations were
taken into consideration and were incorporated in the
final questionnaire.
The proportional stratified sampling technique was used
to draw a sample, on the basis of physician geographical
region, specialty and sex. Excluded from the sample were
physicians who were not authorised to prescribe, either
because they were still interns or because they belonged to
a specialty that is not permitted to prescribe (radiology,
nuclear medicine, microbiology, haematology, anaesthe-
siology, forensic medicine). In Greece, a sample of 1,463
physicians was randomly selected for the purpose of the
study and in Cyprus the questionnaire was sent to 240
physicians also randomly selected in a similar manner. In
both countries, the final questionnaire, a cover letter and
a prepaid return envelope were mailed to the physicians
from the 1st of April 2007 to the 30th of May 2007. The
study is non interventional and it does not involve
patients and hence no ethical approval was needed. None-
theless, it was undertaking according to the ethical stand-
ards and procedures set for this type of research in both
countries and academic institutions involved. Data collec-
tion followed by quality control, codification, recording
and statistical analysis with SPSS (ver15.0).
Results
Demographic characteristics
1,204 physicians from Greece participated in the study
(response rate: 82.3%) and 193 in Cyprus (response rate:
80.4%). In Greece 79.9% were male and 20.1% female,
whilst in Cyprus the percentages were 69.8% and 30.2%,
respectively. As indicated in Table 1, almost half of the
participants in Cyprus (46.8%) were between 41–50 years
of age, whilst in Greece the largest proportion of partici-
pants (35.9%) were aged between 51 and 60 years, thus
representing an older and more experienced sample. In
terms of specialties, in Greece the largest proportion of the
participants were pathologists (14.1%), followed by pae-
diatricians (10.3%) and gynaecologists (9.1%), whilst in
Cyprus the percentages were as following: paediatricians
(17.1%), pathologists (9.6%), gynaecologists and sur-
geons (9.1%). A larger percentage of Cypriot participants
(49.2% versus 26.7%) had a Master of Science (M.Sc)
degree, whilst a larger proportion of Greek physicians
(50.9% versus 30.6%) had participated in a publication
during the previous five years. The great majority of doc-
tors in both countries attend at least one conference per
year. In terms of computer acquaintance the Cypriot phy-
sician cohort appears to have a slight advantage. However,
it needs to be noted that physicians in both countries are
more computer literate than the general population.
Influential factors
As mentioned earlier, the first part of the questionnaire
was intended to investigate the criteria which physicians
take into consideration when making prescribing deci-
sions and their sources of information regarding advances
Table 1: Physicians characteristics in Greece and Cyprus
Greece
(%)
Cyprus
(%)
Sex
Male 79.9 69.8
Female 20.1 30.2
Age
30–40 10.2 17.4
41–50 33.6 46.8
51–60 35.9 33.2
61+ 20.3 2.6
Practicing years
1–5 1.5 4.8
6–10 4.6 11.7
11–15 15.4 21.8
16–20 18.0 29.9
21+ 60.5 38.8
Specialty
Pathologist 14.1 9.6
Paediatrician 10.3 17.1
Gynaecologist 9.1 9.1
Cardiologist 8.6 7.5
Neurologist 7.3 -
Surgeon 6.9 9.1
Other 43.7 47.6
Education/Training
Post graduate 26.7 49.2
Continuous education 50.1 56.5
At least one conference/year 88.8 77.7
At least one publication/5 years 50.9 30.6
Employment Sector
Private 52.8 35.2
Public 15.7 64.2
Social insurance 2.6 -
Multiple 27.3 0.5
Use of PC
High 23.1 19.9
Satisfactory 33.3 52.9
Moderate 26.5 19.4
None 17.1 7.9BMC Health Services Research 2009, 9:150 http://www.biomedcentral.com/1472-6963/9/150
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in pharmaceuticals. As indicated in Table 2, clinical effec-
tiveness is the most important factor, reaching 94.85%
and 93.26% in Greece and Cyprus, respectively and there
was no statistically significant difference between the two.
However, in Greece the drug form, the recommended
daily dose, and patient's own preferences appear to be
more important in the selection of the therapy. With
regard to the cost of drugs to patients, about sixty percent
of physicians take it less or more seriously into considera-
tion when prescribing and there are no major differences
between the two countries. In particular, cost is important
to 46.59% and 51.30% and highly important to 15.95%
and 11.40%, of Greek and Cypriot physicians respec-
tively. The same picture applies in relation to patient
insurance coverage, where about 69.97% and 64.77% of
physicians take it into account in Greece and Cyprus,
respectively.
Table 2: Prescribing behavior of physicians
Which constitutes for you the basic criterion for selecting a drug?
Greece Cyprus Difference p-value
Proven clinical effectiveness 94.85% 93.26% 1.59% 0.392
Pharmaceutical delivery mode 38.21% 9.84% 28.37% 0.000
Recommended daily dose 35.55% 4.15% 31.40% 0.000
Cost to the patient 41.86% 8.29% 33.57% 0.000
Patient preference 11.05% 0.52% 10.53% 0.000
Other 2.49% 3.63% -1.14% 0.406
Which sources do you take into account in justifying your prescription choices?
Greece Cyprus Difference p-value
Publications in medical journals 73.75% 58.55% 15.20% 0.000
Medical textbooks 60.71% 44.04% 16.67% 0.000
Medical congress announcements 70.27% 69.43% 0.84% 0.813
Pharmaceutical sales representatives 51.99% 61.14% -9.15% 0.016
Medical libraries and internet data 
bases
29.49% 28.50% 0.99% 0.757
Others 3.41% 0.52% 2.89% 0.000
For what reasons do you search further information from the above sources on your prescription choice?
Greece Cyprus Difference p-value
Dose 43.02% 41.45% 1.57% 0.668
Adverse drug reactions 81.48% 77.20% 4.28% 0.182
Interactions with other substances 67.11% 63.21% 3.90% 0.292
Provision during pregnacy 53.99% 56.48% -2.49% 0.514
Provision during breast feeding 50.91% 44.56% 6.35% 0.097
Liver-renal disorders 49.25% 55.96% -6.71% 0.079
Chronic disease 43.44% 21.24% 22.20% 0.000
How important is the cost of drug in your prescription selection?
Greece Cyprus Difference p-value
Highly important 15.95% 11.40% 4.55% 0.066
Important 46.59% 51.30% -4.71% 0.218
Not very important 25.83% 30.05% -4.22% 0.225
Not at all important 11.63% 7.25% 4.38% 0.035
To which extend does the existence of patient insurance coverage, influence your selection?
Greece Cyprus Difference p-value
Very much 20.97% 14.51% 6.46% 0.022
Enough 31.11% 23.32% 7.79% 0.021
Rather influence me 17.89% 26.94% -9.05% 0.000
Almost not all 17.14% 20.73% -3.59% 0.239
Not at all 12.90% 14.51% -1.61% 0.548BMC Health Services Research 2009, 9:150 http://www.biomedcentral.com/1472-6963/9/150
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Information sources
Physicians derive information to guide and justify their
prescription choices mainly from medical journals, medi-
cal textbooks, proceedings of medical congresses, sales
representatives and the internet. Nonetheless, there are
some differences between the two countries. Specifically,
Greek doctors rely more on scientific publications and
medical textbooks and less on pharmaceutical representa-
tives. Analytically, medical journals and textbooks are pre-
ferred by 73.75% and 60.71% of Greek doctors,
respectively, compared to 58.55% and 44.04% of Cypri-
ots. On the other hand, pharmaceutical representatives
are preferred as an information source by 61.14% of Cyp-
riot doctors compared to 51.99% of Greeks. Physicians
are looking for information on the above sources mainly
regarding the recommended dose of drugs, their potential
side effects, their use during pregnancy and breast feeding
and their use in the presence of chronic renal or liver dis-
ease. There are no significant differences between the two
countries in relation to the type of enquired information.
Generic drug prescribing
Table 3 contains information regarding the responses of
physicians in relation to generic drug use. It is noteworthy
that about half of doctors in Greece find generic drugs
excellent or satisfactory in terms of efficacy, safety and
effectiveness (51.25%, 54.98% and 52.41% respectively).
However, only 25.20% of them prescribe generic drugs
Table 3: Attitudes of physicians towards generic prescribing
What do you think about the quality of generic drugs in comparison to their branded ones?
Greece Cyprus Difference p-value
Excellent 4.71% 3.11% 1.60% 0.240
Satistactory 46.54% 56.99% -10.45% 0.006
Average 31.92% 32.64% -0.72% 0.842
Rather bad 10.29% 5.18% 5.11% 0.005
Bad 6.54% 2.07% 4.47% 0.000
What do you think about the safety of generics in comparison to their branded ones?
Greece Cyprus Difference p-value
Excellent 5.31% 6.22% -0.91% 0.614
Satistactory 49.57% 61.66% -12.09% 0.001
Average 29.76% 26.42% 3.34% 0.326
Rather bad 8.99% 4.66% 4.33% 0.011
Bad 6.38% 1.04% 5.34% 0.000
What do you think about the effectiveness of generics in comparison to their branded ones?
Greece Cyprus Difference p-value
Excellent 5.79% 2.59% 3.20% 0.015
Satistactory 46.62% 59.59% -12.97% 0.001
Average 33.49% 32.12% 1.37% 0.690
Rather bad 8.40% 3.11% 5.29% 0.000
Bad 5.69% 2.59% 3.10% 0.021
How often do you prescribe a generic product instead of a branded one?
Greece Cyprus Difference p-value
Very often 3.65% 13.99% -10.34% 0.000
Often 21.55% 52.85% -31.30% 0.000
Rarely 47.26% 27.98% 19.28% 0.000
Hardly ever 27.54% 5.18% 22.36% 0.000
Do you think it is feasible to implement a prescribing system based on the INN?
Greece Cyprus Difference p-value
Very feasible 15.21% 17.62% -2.41% 0.397
Feasible 37.62% 39.38% -1.76% 0.631
Rather impossible 30.60% 32.64% -2.04% 0.567
Impossible 16.56% 10.36% 6.20% 0.011BMC Health Services Research 2009, 9:150 http://www.biomedcentral.com/1472-6963/9/150
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often or very often. On the other hand, Cypriots appear to
have a more positive view regarding generic drugs. In par-
ticular, about 60.10%, 67.88% and 62.18% of physicians
respectively find their efficacy, safety and effectiveness
excellent or satisfactory. Finally, regarding the feasibility
of prescribing based on drug substance (International
Non-proprietary Name, INN) only, 37.62% and 15.21%
of Greek physicians consider it rather feasible or very fea-
sible, respectively, while the respective figures for Cypriot
doctors are 39.38% and 17.62%.
New drug prescribing
Table 4 presents information regarding attitudes in rela-
tion to new drugs. The majority, 82.11%, of physicians in
Greece believe that a higher price does not necessarily
imply better patient outcomes. This percentage is some-
what lower, 63.21%, in Cyprus and there are statistically
significant differences between the two countries. There
are also differences in relation to the perceptions of new
drug effectiveness. More specifically, only 62.35% of
Greek physicians believe that they are more effective,
whilst the corresponding number amongst Cypriot doc-
tors is 85.49%. Finally, regarding the sources of informa-
tion about new product launches, these mainly include
medical journals, congresses and sales representatives and
secondarily scientific medical societies and the internet.
Adverse drug reactions and safety
Finally, Table 5 presents information regarding physician
attitudes towards safety issues. As indicated by the find-
ing, physicians get information about side effects prima-
rily from the National Organisation for Medicines and
secondarily from the internet, pharmaceutical companies,
colleagues, and the media. In Cyprus the National Drug
Agency and colleagues appear to have a less important
role. Side effects appear in both countries to be a major
cause of prescription choice modification, as more than
90% of doctors declare that they change their prescription
patterns in cases of side effects. However, that 46.68% of
doctors in Greece declared that they had not encountered
any side effect during the two years prior to the study. It is
also noteworthy that the majority of doctors do not
inform the authorities about their own cases of side
effects.
Discussion
According to the present analysis, the Greek and Cypriot
physicians are well educated and participate frequently in
medical conferences. Furthermore, Greek doctors appear
to have a high publication activity compared to their Cyp-
riot colleagues. This could be partly explained by the fact
that there are many university hospitals and also several
medical journals in Greece. Our results indicate that there
are similarities but also differences between physicians in
Greece and Cyprus regarding the basic criteria upon which
Table 4: Attitudes of physicians towards innovation
In your opinion, does the high price of a new product implies also better effectiveness?
Greece Cyprus Difference p-value
Absolutely 2.90% 4.15% -1.25% 0.395
Enough 14.99% 32.64% -17.65% 0.000
Not really 49.23% 55.96% -6.73% 0.079
Almost not 10.48% 4.66% 5.82% 0.001
Not at all 22.40% 2.59% 19.81% 0.000
Generally, what do you think about the effectiveness of new drug products in comparison to the older ones already 
on the market?
Greece Cyprus Difference p-value
Clearly more effective 18.73% 24.35% -5.62% 0.084
Rather more effective 43.62% 61.14% -17.52% 0.000
Do not differ significantlly 30.15% 14.51% 15.64% 0.000
Do not differ at all 7.49% 0.00% 7.49% 0.000
Which sources do you consult in order to get information for the launch of new drugs?
Greece Cyprus Difference p-value
Scientific journals 78.99% 76.68% 2.31% 0.477
Medical congresses 75.10% 7.25% 63.85% 0.000
Pharmaceutical 
representatives
77.33% 88.08% -10.75% 0.000
Scientific medical societies 38.87% 51.30% -12.43% 0.001
Internet 30.32% 41.45% -11.13% 0.003BMC Health Services Research 2009, 9:150 http://www.biomedcentral.com/1472-6963/9/150
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they select a pharmaceutical treatment. Particularly, the
findings show that drug clinical effectiveness is the most
important factor considered by physicians when they pre-
scribe drugs. However, pharmaceutical form, recom-
mended daily dose, and patient own preferences are taken
into consideration more by Greek physicians compared to
their Cypriots colleagues. Furthermore, doctors in both
countries declare that they are sensitive to the economic
burden imposed upon patients and the health system in
general. It is notable that, although Cypriot physicians
claim that the cost of the drug and insurance coverage are
important factors during prescription, in fact they do not
consider cost as one of the most important criteria for pre-
scription choice.
The results of our study show that there are differences
between the two countries regarding the sources of infor-
mation. Specifically, Greek doctors claim to acquire more
information from publications (journals, proceedings of
conferences and textbooks) and less information from
pharmaceutical sales representatives. The opposite hap-
pens in Cyprus, where proceedings of conferences and
information from sales representatives are in the leading
places, followed by publications. The classification of
these information sources is different in the case of infor-
mation regarding new drugs and adverse drug reactions.
Specifically, in the case of new drugs, sales representatives
are the first source of information in Cyprus and the sec-
ond in Greece, right after scientific or medical journals.
These data are consistent with those from other studies,
where it has been also shown that pharmaceutical sales
representatives are highly influential on decisions to pre-
scribe new drugs [17,18].
Regarding opinions about generics and generic prescrib-
ing there are some differences between physicians in the
two countries. In Greece doctors seem more cautious
about the effectiveness, safety and efficacy of generic
drugs, and as a result they do not prescribe generic drugs
as a means to curtail expenditure. This is not so much the
case in Cyprus, where doctors have a greater trust in
generic drugs and prescribe them to a greater degree. How-
ever, in any case it needs to be stressed that, the percentage
of physicians who believe that the quality of generics is
excellent, is very small in both countries. This finding
could indicate that physicians do not trust the process of
Table 5: Attitudes of physicians towards safety
Which sources do you consult in order to get informed about the ADRs of a drug?
Greece Cyprus Difference p-value
National Medicines Organization 65.70% 48.70% 17.00% 0.000
Internet 33.06% 37.82% -4.76% 0.200
Pharmaceutical representatives 42.61% 41.97% 0.64% 0.866
Media 16.86% 11.92% 4.94% 0.052
Colleagues 38.54% 21.24% 17.30% 0.000
Other 4.32% 11.40% 7.08% 0.001
The appearance of ADRs affects your prescribing decision?
Greece Cyprus Difference p-value
Very much 51.21% 43.01% 8.20% 0.030
A lot 43.13% 47.15% -4.02% 0.300
A little 4.91% 9.84% -4.93% 0.026
Not at all 0.75% 0.00% 0.75% 0.000
How many times have an ADR appeared in your patients in the past two years?
Greece Cyprus Difference p-value
None 46.68% 8.81% 37.87% 0.000
1–5 times 46.26% 57.51% -11.25% 0.004
6–10 times 5.04% 19.69% -14.65% 0.000
More 2.02% 13.99% -11.97% 0.000
For such cases did you send a "yellow card*" to inform the authorities?
Greece Cyprus Difference p-value
Yes 37.43% 11.92% 25.51% 0.000
No 62.57% 88.08% -25.51% 0.000
*Yellow card is a form that needs to be filled by the physician if side effects appear in order to inform the authorities.BMC Health Services Research 2009, 9:150 http://www.biomedcentral.com/1472-6963/9/150
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approval and certification for generic products. The pessi-
mistic and negative view in Greece needs further investi-
gation in order to be addressed, as generic substitution is
a major cost containment measure in most countries. Per-
haps the low generic drug use in this country can be
explained through the combination of several factors. As
noted above a low generic quality perception prevails.
This is combined with no major price differentials
between branded and generic drugs, which eliminates the
financial motive for the substitution. Furthermore, in
Greece there are no financial incentives to motivate physi-
cians to prescribe generics and to promote the generic
market.
Finally, in the case of adverse drug reactions physicians are
informed primarily by the National Organisation of Med-
icines and secondly by sales representatives. This is
expected since the National Organisation of Medicines is
responsible for the assessment of safety and the pharma-
covigilance of medicinal products. Even though adverse
drug reactions may not appear very often, they do have a
profound effect on a physician prescribing patterns, so
doctors seek information in order to be protected and pre-
pared. It is notable, however, that when they encounter
such problems physicians rarely inform the authorities
accordingly, perhaps because they do not want to
acknowledge the fact that their patients had side effects, or
they do not evaluate the side effect as important. This
finding is confirmed by data from the National Organisa-
tion for Medicines (EOF) in Greece. According to the
Organisation, the reports about adverse drug reactions
come mainly from pharmaceutical companies and from
hospitals and to a much lesser degree from individual
physicians [19]. For this reason, a campaign is under way
in Greece aiming towards motivating more physicians to
fill out the yellow card when they encounter an adverse
drug reaction.
In conclusion, the findings of this study are in line to
those of other published studies regarding physician pre-
scribing behaviour and attitudes. More specifically, the
issues of drug cost and patient insurance coverage concern
the majority of physicians, who take these factors into
consideration during their prescribing decisions. Results
from a qualitative study in Denmark showed that drug
price was considered an important factor influencing pre-
scribing decision. Additionally, pharmaceutical industry
sales representatives influenced physicians significantly
[20]. Reichert at al showed in their study that physicians
felt the cost of medicines to be an important criterion in
prescription choice and this was even more important
when patients were not insured [21]. In addition, our
results are comparable to those of two other studies
regarding opinions about generics and generic substitu-
tion [22,23]. Finally, a study that was carried out in 2005
in New Zealand, regarding the information sources which
are mostly used by physicians, had similar results to our
own. It showed that publications and pharmaceutical
sales representatives were the most popular sources of
information and that internet-based sources were used by
half of the participants [24].
The present study is subject to all limitations that apply to
surveys where postal questionnaires are used as a tool to
extract data [25]. Nonetheless, the high response rate in
both countries may allow us to believe that the study was
successful. Another limitation is the lack of distinction
between primary and secondary care physicians, which
would have allowed a better comparison with other stud-
ies in this field. However, this parameter was not taken
into account during the study design because, as men-
tioned at the beginning of this paper, Greece and Cyprus
have no gate-keeping systems and patients have free
access to every physician of every specialty and level of
care.
Conclusion
The present article provides valuable information regard-
ing the prescribing behaviour of doctors in Greece and
Cyprus. Further analysis will help us to understand further
the association between prescription choices and physi-
cian characteristics. These insights will help policy makers
in both countries to develop measures which could be
used to achieve to greater clinical effectiveness and eco-
nomic efficiency from drug prescribing.
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